Votes are still being accepted for the shortlist of companies in each category! Show your support for VGXI by supporting us in the category of “Best Contract Manufacturing Organization” AND “Best Production/Process Development” for the Vaccine Industry Excellence Awards. Winners will be announced at the World Vaccine Congress in Washington DC in April, 2017. Follow this link to… Read More »
On November 18, 2016 VGXI hosted a roundtable discussion with US Congressman Pete Olson and key biotech industry leaders. From left: U.S. Congressman Pete Olson; Ann Tanabe, CEO of BioHouston; Young Park, CEO of GeneOne Life Science; Jim Greenwood, President of BIO; Dorothy Peterson, VP of Operations at VGXI; and Tom Kowalski, President and CEO… Read More »
SEOUL, KOREA (PRWEB) JULY 26, 2016 GeneOne Life Science, Inc. (“GeneOne” KOSPI: 011000) today announced the dosing of the first subjects in its multi-center Phase I trial to evaluate the Zika DNA vaccine (GLS-5700). Refer to ClinicalTrials.Gov, study number NCT02809443. GeneOne has received approval from both the US FDA and Health Canada’s Health Products and… Read More »
On July 13th, 2016 VGXI was featured on KPRC Channel 2 News for their role in manufacturing the first Zika DNA Vaccine approved by the FDA for testing in human clinical trials. Follow this this link or click below to read the full story and watch the video: For more information, contact: Christy Franco, PhD… Read More »
U.S. Congressman Kevin Brady visits VGXI to celebrate the grand opening for their new small scale cGMP manufacturing facility, located in The Woodlands, TX. VGXI Ribbon Cutting, from left: J.J. Hollie, President and CEO of The Woodlands Chamber of Commerce; U.S. Congressman Kevin Brady; Young Park, CEO of GeneOne Life Science; Dorothy Peterson, VP of… Read More »
Come by Booth #5533 to meet us and find out more about VGXI’s process and services! We also welcome requests for partnering meetings during the conference. Biotechnology Industry Organization International Convention June 6-9, 2015 Moscone Convention Center San Francisco, CA Not yet registered? Follow the link below for registration information.
Did you miss us at ASGCT? Download our poster at the link below: Challenges of Production of Nanoplasmid™ with Large Gene insert using the HyperGRO™ Fermentation Process Presented on Friday, May 6, 2016 from 6:00 pm – 8:00 pm Session Information: Vector and Cell Engineering/Manufacturing II Location: Exhibit Hall C & B South Abstract #712… Read More »
American Society of Gene & Cell Therapy 2016 Annual Meeting May 4-7th, 2015 Marriott Wardman Park Hotel Washington DC “Challenges of Production of NanoPlasmid with Large Gene insert using the HyperGRO™ Fermentation Process” Session Information: Vector and Cell Engineering/Manufacturing II Friday, May 6, 2016 from 6:00 pm – 8:00 pm Location: Exhibit Hall C &… Read More »
WVC is the ultimate meeting place for all vaccine experts worldwide. 7 Conferences. 3 Days. 1 Event! March 29-31st, 2016 Grand Hyatt, Washington D.C. Planning to attend? Contact us today to request a meeting and find out more about VGXI’s process and services!
Are you interested in learning more about VGXI’s plasmid production process and GMP services? Contact Us today, or request a meeting through PartneringONE. BIO Europe 2015 November 2-4th, 2015 International Congress Center Munich (ICM) Munich, Germany
On June 18th, 2015 VGXI celebrated the opening of the Advanced Biopharmaceuticals International Center of Support (ABICS) at their facility in The Woodlands, TX. View the video below. In response to the recent MERS outbreak, the Texas-based clinical manufacturing organization, VGXI has rapidly mobilized in collaboration with the Korean company GeneOne Life sciences to expedite… Read More »
VGXI supports expedited development and scale-up of multiple vaccine candidates to treat Ebola through a DARPA funded collaboration. Click below to view the video. US Congressman Kevin Brady visited the VGXI manufacturing facility in The Woodlands, TX on May 4th, 2015 to tour the production plant and provide a statement on the impact of this… Read More »